Tengion, Inc. (OTCMKTS:TNGN) Jumps on Expectations of Investors’ Forum
We are still waiting for Tengion, Inc. (OTCMKTS:TNGN) make a more discernible move in its price, as for now what we have are daily spikes that hardly form a trend in the early months of 2014. But Wednesday arrived with record volumes, as about five million shares were bought up, for a dollar volume of $1.3 million. The price budget a little, up 23% to $0.26, a reasonable daily addition at this price range. 
TNGN has not seen a formal promotion, but it had the next best thing- a presentation at an investors’ forum coming up next week. The news landed on Tuesday, and helped lift the ticker up. The 26th annual ROTH conference will take place in Dana Point, California, and is an event for fast-growth companies of various industries. The president of TNGN, John L. Miclot, will present on March 10th.
TNGN is a newcoming biotech ticker with great ambitions in the field of regenerative medicine. Among OTC companies, qualities differ, but TNGN is relatively well padded financially, though carrying the burden of its development process:
- cash: $7.5 million
- total assets: $12.4 million
- current liabilities: $13.7 million
- total liabilities: $23.7 million
- revenue since inception: $0
- net loss: $7.2 million
But what matters to biotech developers is the future promise, and the timely delivery of positive information. For other pharmaceutical companies as well, the long waiting time often leads to loss of investors’ enthusiasm, and downward shifts in price. It takes a concerted effort of positive news to bring the ticker back into the spotlight.
Marina Biotech, Inc. (OTCMKTS:MRNA) illustrated a similar run of events, as it reinvigorated its PR activity in the new year and shot upwards as it received a patent protection for one of its therapies. MRNA is back at $1.38, after it slumped for a while following a temporary peak at $1.70.
The lack of developments left Titan Pharmaceuticals, Inc. (OTCBB:TTNP) moving sideways for months, although there were expectations that the ticker would soon conquer the dollar levels again. TTNP had much expectations of its newest therapy, but when approval from the FDA became problematic, the stock price gapped down by 75% and never really recovered. Currently TTNP hovers between 60 and 70 cents.
TNGN, much like other biotech tickers, shows the potential for long-term gains, or at least the need to wait out the weaker periods with the hope that news, PR or the occasional promotion would bring more robust gains. Unlike recent mover Therapy Cells, Inc. (OTCMKTS:TCEL), this company shows better solidity in a similar field, using the patient’s own cells to regenerate organs and tissues. If you like the promise of this sector, keep in mind that sentiment and momentum are sometimes more important for the stock price, and avoid over-investing, to avoid painful losses as the stock price reverses.
